Study of ZE74-0282 for Patients With JAK2 V617F Positive Blood Cancers
NCT07529951
·
clinicaltrials.gov ↗
PHASE1
Phase
NOT_YET_RECRUITING
Status
60
Enrollment
INDUSTRY
Sponsor class
Conditions
Polycythemia Vera (PV)
Myelofibrosis (MF)
Interventions
DRUG:
ZE74-0282
Sponsor
Eilean Therapeutics